Pfizer snags Encysive in $195M buyout

Pfizer has demonstrated once again just how interested it is in biotech with its $195 million deal to buy Encysive. The buyout expands Pfizer's pipeline for high blood pressure therapies, delivering the rights to Thelin. Pfizer says it will mount a late-phase trial to obtain FDA approval for Thelin, which has already been approved in a long lineup of European countries as well as Canada and Australia. Pfizer is making a $2.35 a share cash tender offer. Encysive's board has signed off on the deal, which is expected to close in the second quarter.

"The acquisition of Encysive will add growing, near-term revenue from the European market and increase our already strong presence in the cardio-respiratory arena with a product that complements Revatio, a PAH treatment that was discovered and developed by Pfizer researchers," said Ian Read, president of Pfizer's worldwide pharmaceutical operations. "We look forward to applying Pfizer's significant resources to the launch of Thelin in additional countries."

- see the release
- read the AP report

Related Articles:
Pfizer focuses on expanding inhaled meds R&D. Report
Pfizer grabs osteoarthritis therapy in $250M deal. Report
Speculation soars over Pfizer's interest in biotech. Report
Struggling Encysive brings in Morgan Stanley. Report
Encysive CEO departs as pink slips fly. Report

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.